Earnings Analyzer
Stock earnings page

ACSAY (ACSAY)

Track the next or latest earnings date for ACSAY, review consensus estimates, and see cached AI analysis for recent quarterly results.

Recent earnings news

Avidity Partners Management LP Sells 93,933 Shares of ACADIA Pharmaceuticals Inc. $ACAD - Defense World
defenseworld.net · 2026-08-01T07:50:03

Avidity Partners Management LP cut its holdings in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) by 87.9% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm owned 12,967 shares of the biopharmaceutical company’s stock after selling ...

Acadia Pharmaceuticals EVP Thompson sells $432,662 in stock By Investing.com
ca.investing.com · 2026-07-31T22:32:10

Endeavour Silver Corp (EXK) (Q2 2026) Earnings Call Highlights: Record Production and Revenue ... ... Elizabeth H.Z. Thompson, Executive Vice President and Head of Research & Development at ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD), sold company common stock valued at approximately $432,662 ...

Academy Sports & Outdoors (NASDAQ:ASO): A Decent Value Play with Solid Fundamentals | ChartMill.com
chartmill.com · 2026-07-31T08:50:33

Academy Sports & Outdoors (ASO) offers decent value with a low P/E of 8.09, solid profitability, and stable growth, making it a balanced pick for value investors.

AcadeMedia Issues New Class C Shares to Support Long-Term Incentive Program - TipRanks.com
tipranks.com · 2026-07-31T06:34:57

An announcement from AcadeMedia AB ( ($SE:ACAD) ) is now available. AcadeMedia AB has expanded its share capital and voting rights in July 2026 through the issuance...

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
defenseworld.net · 2026-07-31T06:15:14

Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Free Report) have received an average rating of “Moderate Buy” from the eighteen ratings firms that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, four ...

Latest earnings date

Feb 19, 2026

Time not specified

Fiscal quarter: 2025-12-31

EPS estimate: $0.00

Revenue estimate: N/A

Market cap: N/A

Analysis snapshot

No cached AI earnings analysis is available for this stock yet. Check back after the company reports or open the app to generate a fresh analysis.

Recent earnings history

Browse the calendar week
Date Quarter Report window EPS est. Revenue est.
Feb 19, 2026 2025-12-31 Time not specified $0.00 N/A